FLORHAM PARK, N.J., May 15, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that the company is scheduled to participate in the following investor conferences in May and June:

H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ in New York, NY
Date: Tuesday, May 20, 2025
Live Webcast: 4:00 p.m. ET
Company to participate in one-on-one meetings throughout the conference

Jefferies Global Healthcare Conference in New York, NY
Date: Thursday, June 5, 2025
Live Webcast: 9:55 a.m. ET
Company to participate in one-on-one meetings throughout the conference

Goldman Sachs 46th Annual Global Healthcare Conference 2025 in Miami Beach, FL
Date: Wednesday, June 11, 2025
Live Webcast: 10:40 a.m. ET
Company to participate in one-on-one meetings throughout the conference

To access the live webcast and archived recordings of each event, visit the News & Events section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. Recordings will be available for 90 days following the conclusion of each meeting.

About Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB) that is currently marketed in the United States as VOQUEZNA^® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, in addition to VOQUEZNA^® TRIPLE PAK^® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA^® DUAL PAK^® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.

MEDIA CONTACT
Nick Benedetto
1-877-742-8466
This email address is being protected from spambots. You need JavaScript enabled to view it.

INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
This email address is being protected from spambots. You need JavaScript enabled to view it.

© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.